Gain-of-function variants in the ion channel gene TRPM3 underlie a spectrum of neurodevelopmental disorders

  1. Lydie Burglen
  2. Evelien Van Hoeymissen
  3. Leila Qebibo
  4. Magalie Barth
  5. Newell Belnap
  6. Felix Boschann
  7. Christel Depienne
  8. Katrien De Clercq
  9. Andrew GL Douglas
  10. Mark P Fitzgerald
  11. Nicola Foulds
  12. Catherine Garel
  13. Ingo Helbig
  14. Katharina Held
  15. Denise Horn
  16. Annelies Janssen
  17. Angela M Kaindl
  18. Vinodh Narayanan
  19. Christine Prager
  20. Mailys Rupin
  21. Alexandra Afenjar
  22. Siyuan Zhao
  23. Vincent Th Ramaekers
  24. Sarah M Ruggiero
  25. Simon Thomas
  26. Stéphanie Valence
  27. Lionel Van Maldergem
  28. Tibor Rohacs
  29. Diana Rodriguez
  30. David Dyment
  31. Thomas Voets  Is a corresponding author
  32. Joris Vriens  Is a corresponding author
  1. INSERM UMR 1163, France
  2. KU Leuven, Belgium
  3. Hôpitaux Universitaires Paris-Ouest, France
  4. Centre Hospitalier Universitaire d'Angers, France
  5. Translational Genomics Research Institute, United States
  6. Charité - Universitäts medizin Berlin, Germany
  7. Essen University Hospital, United States
  8. University Hospital Southampton NHS Foundation Trust, United Kingdom
  9. Children's Hospital of Philadelphia, United States
  10. Charité - Universitätsmedizin Berlin, Germany
  11. Rutgers, The State University of New Jersey, United States
  12. University of Liège, Belgium
  13. Salisbury District Hospital, United Kingdom
  14. Centre Hospitalier Universitaire de Besançon, France
  15. University of Ottawa, Canada
  16. VIB-KU Leuven Center for Brain & Disease Research, Belgium

Abstract

TRPM3 is a temperature- and neurosteroid-sensitive plasma membrane cation channel expressed in a variety of neuronal and non-neuronal cells. Recently, rare de novo variants in TRPM3 were identified in individuals with developmental and epileptic encephalopathy (DEE), but the link between TRPM3 activity and neuronal disease remains poorly understood. We previously reported that two disease-associated variants in TRPM3 lead to a gain of channel function (Van Hoeymissen et al., 2020; Zhao et al., 2020). Here, we report a further ten patients carrying one of seven additional heterozygous TRPM3 missense variants. These patients present with a broad spectrum of neurodevelopmental symptoms, including global developmental delay, intellectual disability, epilepsy, musculo-skeletal anomalies, and altered pain perception. We describe a cerebellar phenotype with ataxia or severe hypotonia, nystagmus, and cerebellar atrophy in more than half of the patients. All disease-associated variants exhibited a robust gain-of-function phenotype, characterized by increased basal activity leading to cellular calcium overload and by enhanced responses to the neurosteroid ligand pregnenolone sulphate, when co-expressed with wild-type TRPM3 in mammalian cells. The antiseizure medication primidone, a known TRPM3 antagonist, reduced the increased basal activity of all mutant channels. These findings establish gain-of-function of TRPM3 as the cause of a spectrum of autosomal dominant neurodevelopmental disorders with frequent cerebellar involvement in humans, and provide support for the evaluation of TRPM3 antagonists as a potential therapy.

Data availability

Raw data for the following figures are made available via figshare (https://doi.org/10.6084/m9.figshare.21799604): Figure 1 - Figure Supplement 1; Figure 3; Figure 3 - Figure Supplement 1, 2, 3 and 4; Figure 4; Figure 4 - Figure Supplement 1, 2 and 3.

The following data sets were generated

Article and author information

Author details

  1. Lydie Burglen

    Developmental Brain Disorders Laboratory, INSERM UMR 1163, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Evelien Van Hoeymissen

    Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3897-8998
  3. Leila Qebibo

    Département de Génétique, Hôpitaux Universitaires Paris-Ouest, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Magalie Barth

    Department of Genetics, Centre Hospitalier Universitaire d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Newell Belnap

    Neurogenomics Division, Translational Genomics Research Institute, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Felix Boschann

    Institute of Medical Genetics and Human Genetics, Charité - Universitäts medizin Berlin, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Christel Depienne

    Institute of Human Genetics, Essen University Hospital, Essen, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Katrien De Clercq

    Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  9. Andrew GL Douglas

    University Hospital Southampton NHS Foundation Trust, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Mark P Fitzgerald

    Children's Hospital of Philadelphia, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Nicola Foulds

    Wessex Clinical Genetics Service, University Hospital Southampton NHS Foundation Trust, Wessex, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Catherine Garel

    Département de Génétique, Hôpitaux Universitaires Paris-Ouest, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  13. Ingo Helbig

    Children's Hospital of Philadelphia, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Katharina Held

    Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  15. Denise Horn

    Institute of Medical Genetics and Human Genetics, Charité - Universitäts medizin Berlin, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0870-8911
  16. Annelies Janssen

    Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6735-8248
  17. Angela M Kaindl

    Institute of Cell Biology and Neurobiology, Charité - Universitätsmedizin Berlin, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9454-206X
  18. Vinodh Narayanan

    Neurogenomics Division, Translational Genomics Research Institute, Phoenix, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0658-3847
  19. Christine Prager

    Institute of Medical Genetics and Human Genetics, Charité - Universitäts medizin Berlin, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  20. Mailys Rupin

    Department of Neuropediatrics, Centre Hospitalier Universitaire d'Angers, Angers, France
    Competing interests
    The authors declare that no competing interests exist.
  21. Alexandra Afenjar

    Developmental Brain Disorders Laboratory, INSERM UMR 1163, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  22. Siyuan Zhao

    Department of Pharmacology, Physiology and Neuroscience, Rutgers, The State University of New Jersey, Newark, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2005-9440
  23. Vincent Th Ramaekers

    Division Neuropediatrics, University of Liège, Liège, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  24. Sarah M Ruggiero

    Children's Hospital of Philadelphia, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  25. Simon Thomas

    Wessex Regional Genetics Laboratory, Salisbury District Hospital, Wessex, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  26. Stéphanie Valence

    Département de Génétique, Hôpitaux Universitaires Paris-Ouest, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  27. Lionel Van Maldergem

    Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Besancon, France
    Competing interests
    The authors declare that no competing interests exist.
  28. Tibor Rohacs

    Department of Pharmacology, Physiology and Neuroscience, Rutgers, The State University of New Jersey, Newark, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3580-2575
  29. Diana Rodriguez

    Département de Génétique, Hôpitaux Universitaires Paris-Ouest, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  30. David Dyment

    Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada
    Competing interests
    The authors declare that no competing interests exist.
  31. Thomas Voets

    VIB-KU Leuven Center for Brain & Disease Research, Leuven, Belgium
    For correspondence
    thomas.voets@kuleuven.be
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5526-5821
  32. Joris Vriens

    Department of Development and Regeneration, KU Leuven, Leuven, Belgium
    For correspondence
    Joris.Vriens@kuleuven.be
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2502-0409

Funding

Flanders' FOOD (G.0D1417N)

  • Joris Vriens

Flanders' FOOD (G.084515N)

  • Joris Vriens

Flanders' FOOD (G.0A6719N)

  • Joris Vriens

Flanders' FOOD (11E782)

  • Evelien Van Hoeymissen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study was performed in accordance with the guidelines specified by the institutional review boards and ethics committees at each institution. Information of institutional protocols are provided in the section of Material & Methods. All parents agreed on sharing and publicing the patients' information.Patients information:patient 1, 3, 4, 7: Written informed consent was obtained from the parents of the probands for molecular genetic analysis and possible publication of the anonymized clinical data. The study was done in accordance with local research and ethics requirements.patient 2: Parents signed an informed consent, received a genetic counselling before and after the analysis, and the genetic study was performed in accordance with German and French ethical requirements and laws.patient 5: UK ethical approval by the Cambridge South Research Ethics Committee (10/H0305/83)patient 6: outine clinical care within the UK National Health Service, and so no specific institutional ethical approval was requiredpatient 8: Declaration of Helsinki with local approval by the Children's Hospital of Philadelphia (CHOP) Institutional Review Board (IRB 15-12226).patient 9: The participating family signed the IRB research protocol of the University of Pennsylvania division of Neurologypatient 10: The study protocol and consent documents were approved by the Western Institutional Review Board (WIRB # 20120789). The retrospective analysis of epilepsy patient data was approved by the local ethics committees of the Charité (approval no. EA2/084/18)

Copyright

© 2023, Burglen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,032
    views
  • 507
    downloads
  • 13
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lydie Burglen
  2. Evelien Van Hoeymissen
  3. Leila Qebibo
  4. Magalie Barth
  5. Newell Belnap
  6. Felix Boschann
  7. Christel Depienne
  8. Katrien De Clercq
  9. Andrew GL Douglas
  10. Mark P Fitzgerald
  11. Nicola Foulds
  12. Catherine Garel
  13. Ingo Helbig
  14. Katharina Held
  15. Denise Horn
  16. Annelies Janssen
  17. Angela M Kaindl
  18. Vinodh Narayanan
  19. Christine Prager
  20. Mailys Rupin
  21. Alexandra Afenjar
  22. Siyuan Zhao
  23. Vincent Th Ramaekers
  24. Sarah M Ruggiero
  25. Simon Thomas
  26. Stéphanie Valence
  27. Lionel Van Maldergem
  28. Tibor Rohacs
  29. Diana Rodriguez
  30. David Dyment
  31. Thomas Voets
  32. Joris Vriens
(2023)
Gain-of-function variants in the ion channel gene TRPM3 underlie a spectrum of neurodevelopmental disorders
eLife 12:e81032.
https://doi.org/10.7554/eLife.81032

Share this article

https://doi.org/10.7554/eLife.81032

Further reading

    1. Cell Biology
    Mitsuhiro Abe, Masataka Yanagawa ... Yasushi Sako
    Research Article

    Anionic lipid molecules, including phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), are implicated in the regulation of epidermal growth factor receptor (EGFR). However, the role of the spatiotemporal dynamics of PI(4,5)P2 in the regulation of EGFR activity in living cells is not fully understood, as it is difficult to visualize the local lipid domains around EGFR. Here, we visualized both EGFR and PI(4,5)P2 nanodomains in the plasma membrane of HeLa cells using super-resolution single-molecule microscopy. The EGFR and PI(4,5)P2 nanodomains aggregated before stimulation with epidermal growth factor (EGF) through transient visits of EGFR to the PI(4,5)P2 nanodomains. The degree of coaggregation decreased after EGF stimulation and depended on phospholipase Cγ, the EGFR effector hydrolyzing PI(4,5)P2. Artificial reduction in the PI(4,5)P2 content of the plasma membrane reduced both the dimerization and autophosphorylation of EGFR after stimulation with EGF. Inhibition of PI(4,5)P2 hydrolysis after EGF stimulation decreased phosphorylation of EGFR-Thr654. Thus, EGFR kinase activity and the density of PI(4,5)P2 around EGFR molecules were found to be mutually regulated.

    1. Cell Biology
    Jeongsik Kim, Dahyun Kim ... Dae-Sik Lim
    Research Article

    Cell survival in metazoans depends on cell attachment to the extracellular matrix (ECM) or to neighboring cells. Loss of such attachment triggers a type of programmed cell death known as anoikis, the acquisition of resistance to which is a key step in cancer development. The mechanisms underlying anoikis resistance remain unclear, however. The intracellular F-actin cytoskeleton plays a key role in sensing the loss of cell–ECM attachment, but how its disruption affects cell fate during such stress is not well understood. Here, we reveal a cell survival strategy characterized by the formation of a giant unilocular vacuole (GUVac) in the cytoplasm of the cells whose actin cytoskeleton is disrupted during loss of matrix attachment. Time-lapse imaging and electron microscopy showed that large vacuoles with a diameter of >500 nm accumulated early after inhibition of actin polymerization in cells in suspension culture, and that these vacuoles subsequently coalesced to form a GUVac. GUVac formation was found to result from a variation of a macropinocytosis-like process, characterized by the presence of inwardly curved membrane invaginations. This phenomenon relies on both F-actin depolymerization and the recruitment of septin proteins for micron-sized plasma membrane invagination. The vacuole fusion step during GUVac formation requires PI(3)P produced by VPS34 and PI3K-C2α on the surface of vacuoles. Furthermore, its induction after loss of matrix attachment conferred anoikis resistance. Our results thus show that the formation of a previously unrecognized organelle promotes cell survival in the face of altered actin and matrix environments.